Back to top
more

CASI Pharmaceuticals Inc. (CASI)

(Delayed Data from NSDQ)

$5.48 USD

5.48
21,567

-0.14 (-2.48%)

Updated Nov 8, 2024 01:24 PM ET

After-Market: $5.62 +0.14 (2.54%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -15.79% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 21.05% and 58.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business

by Zacks Equity Research

CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.

USANA Health Sciences (USNA) Q3 Earnings Miss Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 36.17% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -42.86% and 6.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 163.83% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of -2.42% and 3.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 13.85% and 19.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 1.59% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon.

CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 44.44% and 16.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.